-
Something wrong with this record ?
Palmitoylated PrRP analog decreases body weight in DIO rats but not in ZDF rats
M. Holubová, J. Zemenová, B. Mikulášková, V. Panajotova, J. Stöhr, M. Haluzík, J. Kuneš, B. Železná, L. Maletínská,
Language English Country England, Great Britain
Document type Journal Article
PubMed
26906745
DOI
10.1530/joe-15-0519
Knihovny.cz E-resources
- MeSH
- Appetite Depressants pharmacology MeSH
- Diet, High-Fat adverse effects MeSH
- Diabetes Mellitus, Experimental metabolism MeSH
- Glucose Tolerance Test MeSH
- Prolactin-Releasing Hormone analogs & derivatives pharmacology MeSH
- Liver drug effects metabolism MeSH
- Rats MeSH
- Receptors, Leptin deficiency MeSH
- Lipoylation MeSH
- RNA, Messenger genetics metabolism MeSH
- Lipid Metabolism drug effects genetics MeSH
- Mice MeSH
- Obesity drug therapy metabolism pathology MeSH
- Rats, Sprague-Dawley MeSH
- Rats, Zucker MeSH
- Eating drug effects MeSH
- Drug Design MeSH
- Body Weight drug effects MeSH
- Adipose Tissue drug effects metabolism MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
Anorexigenic neuropeptides produced and acting in the brain have the potential to decrease food intake and ameliorate obesity, but are ineffective after peripheral application, owing to a limited ability to cross the blood-brain barrier. We have designed lipidized analogs of prolactin-releasing peptide (PrRP), which is involved in energy balance regulation as demonstrated by obesity phenotypes of both Prrp-knockout and Prrp receptor-knockout mice. The aim of this study was to characterize the subchronic effect of a palmitoylated PrRP analog in two rat models of obesity and diabetes: diet-induced obese Sprague-Dawley rats and leptin receptor-deficient Zucker diabetic (ZDF) rats. In the rats with diet-induced obesity (DIO), a two-week intraperitoneal treatment with palmitoylated PrRP lowered food intake by 24% and body weight by 8%. This treatment also improved glucose tolerance and tended to decrease leptin levels and adipose tissue masses in a dose-dependent manner. In contrast, in ZDF rats, the same treatment with palmitoylated PrRP lowered food intake but did not significantly affect body weight or glucose tolerance, probably in consequence of severe leptin resistance due to a nonfunctional leptin receptor. Our data indicate a good efficacy of lipidized PrRP in DIO rats. Thus, the strong anorexigenic, body weight-reducing, and glucose tolerance-improving effects make palmitoylated PrRP an attractive candidate for anti-obesity treatment.
1st Faculty of MedicineCharles University Prague Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17024153
- 003
- CZ-PrNML
- 005
- 20170830100951.0
- 007
- ta
- 008
- 170720s2016 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1530/JOE-15-0519 $2 doi
- 035 __
- $a (PubMed)26906745
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Holubová, Martina $u Institute of Organic Chemistry and BiochemistryAcademy of Sciences of the Czech Republic, Prague, Czech Republic.
- 245 10
- $a Palmitoylated PrRP analog decreases body weight in DIO rats but not in ZDF rats / $c M. Holubová, J. Zemenová, B. Mikulášková, V. Panajotova, J. Stöhr, M. Haluzík, J. Kuneš, B. Železná, L. Maletínská,
- 520 9_
- $a Anorexigenic neuropeptides produced and acting in the brain have the potential to decrease food intake and ameliorate obesity, but are ineffective after peripheral application, owing to a limited ability to cross the blood-brain barrier. We have designed lipidized analogs of prolactin-releasing peptide (PrRP), which is involved in energy balance regulation as demonstrated by obesity phenotypes of both Prrp-knockout and Prrp receptor-knockout mice. The aim of this study was to characterize the subchronic effect of a palmitoylated PrRP analog in two rat models of obesity and diabetes: diet-induced obese Sprague-Dawley rats and leptin receptor-deficient Zucker diabetic (ZDF) rats. In the rats with diet-induced obesity (DIO), a two-week intraperitoneal treatment with palmitoylated PrRP lowered food intake by 24% and body weight by 8%. This treatment also improved glucose tolerance and tended to decrease leptin levels and adipose tissue masses in a dose-dependent manner. In contrast, in ZDF rats, the same treatment with palmitoylated PrRP lowered food intake but did not significantly affect body weight or glucose tolerance, probably in consequence of severe leptin resistance due to a nonfunctional leptin receptor. Our data indicate a good efficacy of lipidized PrRP in DIO rats. Thus, the strong anorexigenic, body weight-reducing, and glucose tolerance-improving effects make palmitoylated PrRP an attractive candidate for anti-obesity treatment.
- 650 _2
- $a tuková tkáň $x účinky léků $x metabolismus $7 D000273
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a anorektika $x farmakologie $7 D001067
- 650 _2
- $a tělesná hmotnost $x účinky léků $7 D001835
- 650 _2
- $a experimentální diabetes mellitus $x metabolismus $7 D003921
- 650 _2
- $a dieta s vysokým obsahem tuků $x škodlivé účinky $7 D059305
- 650 _2
- $a racionální návrh léčiv $7 D015195
- 650 _2
- $a přijímání potravy $x účinky léků $7 D004435
- 650 _2
- $a glukózový toleranční test $7 D005951
- 650 _2
- $a metabolismus lipidů $x účinky léků $x genetika $7 D050356
- 650 _2
- $a lipoylace $7 D054878
- 650 _2
- $a játra $x účinky léků $x metabolismus $7 D008099
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a obezita $x farmakoterapie $x metabolismus $x patologie $7 D009765
- 650 _2
- $a hormon uvolňující prolaktin $x analogy a deriváty $x farmakologie $7 D056690
- 650 _2
- $a messenger RNA $x genetika $x metabolismus $7 D012333
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Sprague-Dawley $7 D017207
- 650 _2
- $a potkani Zucker $7 D011924
- 650 _2
- $a leptinové receptory $x nedostatek $7 D054411
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Zemenová, Jana $u Institute of Organic Chemistry and BiochemistryAcademy of Sciences of the Czech Republic, Prague, Czech Republic Department of Analytical ChemistryUniversity of Chemistry and Technology, Prague, Czech Republic.
- 700 1_
- $a Mikulášková, Barbora $u Institute of Organic Chemistry and BiochemistryAcademy of Sciences of the Czech Republic, Prague, Czech Republic Institute of PhysiologyAcademy of Sciences of the Czech Republic, Prague, Czech Republic.
- 700 1_
- $a Panajotova, Vladimíra $u Apigenex LimitedPrague, Czech Republic.
- 700 1_
- $a Stöhr, Jiří $u Apigenex LimitedPrague, Czech Republic.
- 700 1_
- $a Haluzík, Martin $u First Faculty of MedicineCharles University, Prague, Czech Republic.
- 700 1_
- $a Kuneš, Jaroslav $u Institute of Organic Chemistry and BiochemistryAcademy of Sciences of the Czech Republic, Prague, Czech Republic Institute of PhysiologyAcademy of Sciences of the Czech Republic, Prague, Czech Republic.
- 700 1_
- $a Železná, Blanka $u Institute of Organic Chemistry and BiochemistryAcademy of Sciences of the Czech Republic, Prague, Czech Republic.
- 700 1_
- $a Maletínská, Lenka $u Institute of Organic Chemistry and BiochemistryAcademy of Sciences of the Czech Republic, Prague, Czech Republic maletin@uochb.cas.cz.
- 773 0_
- $w MED00002653 $t The Journal of endocrinology $x 1479-6805 $g Roč. 229, č. 2 (2016), s. 85-96
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26906745 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170720 $b ABA008
- 991 __
- $a 20170830101539 $b ABA008
- 999 __
- $a ok $b bmc $g 1239834 $s 985066
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 229 $c 2 $d 85-96 $e 20160223 $i 1479-6805 $m Journal of Endocrinology $n J Endocrinol $x MED00002653
- LZP __
- $a Pubmed-20170720
